Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1688 - Cytokeratin 4 is a novel predictive marker in early stage (T1/2) oral tongue squamous cell carcinoma (TSCC)


09 Oct 2016


Poster display


Tomohiro Enokida


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


T. Enokida1, S. Fujii2, M. Takahashi3, T. Wakasugi1, T. Yamazaki1, S. Okano1, R. Hayashi4, M. Tahara1

Author affiliations

  • 1 Department Of Head And Neck Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Division Of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 277-8577 - Kashiwa/JP
  • 3 Department Of Digestive Endoscopy, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 4 Head And Neck Surgery Division, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP


Abstract 1688


We have already shown that cytokeratin 4 (CK4) protein expression is a favorable prognostic factor for the patients with locally advanced TSCC. The aim of this study is to identify predictive markers of TSCC recurrence and cancer specific death among clinicopathological factors including CK4 protein expression.


Two cohorts including discovery (79 cases) and validation (94 cases) cohorts consisting of the patients with primary TSCC were evaluated. Eligibility criteria were as follows: 1) preoperative imaging diagnosis of cT1/2N0; 2) primary partial glossectomy without lymph node dissection; and 3) TSCCs with pT1/2. The relationship between clinicopathological factors and relapse-free survival (RFS) and cancer specific survival (CSS) was statistically analyzed.


Median age, pT, median tumor thickness and rate of positive immunohisthochemical staining for CK4 in tumor cells in discovery cohort were 63 years (26-89), pT1/2 = 47%/53%, 6 mm (0.75-16), and 59%, respectively. 3-year RFS and 3-year CSS rates were 70.3% and 94.5%, respectively. Multivariate analysis indicated that pT [pT2 vs. pT1, hazard ratio (HR) of 2.63], tumor thickness [≥5mm vs.


CK4 is a novel predictive marker for recurrence in early TSCC. The combination of CK4 with clinicopathlogical factors predicted recurrence and cancer specific death in this population.

Clinical trial identification

Legal entity responsible for the study

National cancer center




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings